BCL2 inhibition stimulates dendritic cell function for improved anticancer immunotherapy

Peng Liu; Liwei Zhao; Guido Guido Kroemer; Oliver Kepp

doi:10.1038/s41435-024-00256-9

Article2017

Trial watch: Dendritic cell-based anticancer immunotherapy

Abhishek D. Garg, Mónica Vara‐Pérez, Marco B.E. Schaaf, Patrizia Agostinis, Laurence Zitvogel, Guido Guido Kroemer, Lorenzo Galluzzi

Article2023

The BCL2 inhibitor venetoclax mediates anticancer effects through dendritic cell activation

Peng Liu, Liwei Zhao, Laurence Zitvogel, Oliver Kepp, Guido Guido Kroemer

Article2023

BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance

Liwei Zhao, Peng Liu, Misha Mao, Shuai Zhang, Camille Bigenwald, Charles‐Antoine Dutertre, Christian H.K. Lehmann, Hui Pan, Nicolas Paulhan, Lukas Amon, Aitziber Buqué, Takahiro Yamazaki, Lorenzo Galluzzi, Benoit Kloeckner, Aymeric Silvin, Yuhong Pan, Hui Chen, Ai-Ling Tian, Pierre Ly, Diana Dudziak, Laurence Zitvogel, Oliver Kepp, Guido Guido Kroemer

Article2022

Dendritic cell transfer for cancer immunotherapy

Liwei Zhao, Shuai Zhang, Oliver Kepp, Guido Guido Kroemer, Peng Liu

Preprint2023

Data from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance